UPDATE: Serono Signs $20M Proteomics Deal with Britain s Inpharmatica | GenomeWeb

This story has been updated from a previous version.

GENEVA, July 12 – Swiss biotech company Serono said Thursday it had signed a two-year structural genomics collaboration with Inpharmatica, which could generate more than $20 million in milestone and other payments for the British bioinformatics company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.